Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
Publication year
2019Source
Gynecologic Oncology, 152, 2, (2019), pp. 235-242ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Medical Oncology
IQ Healthcare
Journal title
Gynecologic Oncology
Volume
vol. 152
Issue
iss. 2
Page start
p. 235
Page end
p. 242
Subject
All institutes and research themes of the Radboud University Medical Center; Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health SciencesThis item appears in the following Collection(s)
- Academic publications [204994]
- Faculty of Medical Sciences [81051]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.